Table 1.
The characteristics of patients with invasive pneumococcal disease.
| Antibiotic susceptibility profiles |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (months)/ gender | Underlying diagnosis | Clinical syndrome | Serotype of pneumococcus | Previous PCV type/dose | Length of treatment (days) | Length of hospitalization (days) | Outcome / Any sequela | Penicillins | Macrolides | Fluoro. | |
| Case 1 | 2, Male | No | Meningitis | 15B | PCV13/ 1 | 23 | 36 | Alive/yes | HR | R | S |
| Case 2 | 61, Male | No | Meningitis | 1 | PCV7/ 3 + 1 | 14 | 21 | Alive/yes | S | S | S |
| Case 3 | 51, Male | Oncological malignancy | Bacteremia | 1 | Not vaccinated | 18 | 48 | Alive/no | IR | R | S |
| Case 4 | 8, Male | IMD | Bacteremia | 18F | PCV13/ 3 | 24 | 36 | Alive/no | S | R | S |
| Case 5 | 13, Male | Hydrocephalus with VP shunt | Meningitis | 19F* | PCV13/ 3 + 1 | 6 | 6 | Exitus | IR | R | S |
| Case 6 | 43, Male | Cerebral palsy | Pneumonia | 19F* | PCV13/ 3 + 1 | 12 | 12 | Exitus | HR | R | S |
IMD: Inherited metabolic disorder, VP: Ventriculoperitoneal shunt, HR: High resistance, IR: Intermediate resistance, Fluoro.: Fluoroquinolones, S: Susceptible, R: Resistant,
*
Vaccine failure.